Suppr超能文献

羊毛硫抗生素NAI-107在中性粒细胞减少小鼠大腿感染模型中的体内药代动力学和药效学

In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.

作者信息

Lepak Alexander J, Marchillo Karen, Craig William A, Andes David R

机构信息

Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

William S. Middleton Memorial VA Hospital, Madison, Wisconsin, USA.

出版信息

Antimicrob Agents Chemother. 2015 Feb;59(2):1258-64. doi: 10.1128/AAC.04444-14. Epub 2014 Dec 15.

Abstract

NAI-107 is a novel lantibiotic compound with potent in vitro activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The purpose of this study was to examine the activity of NAI-107 against S. aureus strains, including MRSA, in the neutropenic murine thigh infection model. Serum pharmacokinetics were determined and time-kill studies were performed following administration of single subcutaneous doses of 5, 20, and 80 mg/kg body weight. The dose fractionation included total doses ranging from 1.56 to 400 mg/kg/72 h, divided into 1, 2, 3, or 6 doses. Studies of treatment effects against 9 S. aureus strains (4 methicillin-susceptible Staphylococcus aureus [MSSA] and 5 MRSA) using a 12-h dosing interval and total dose range of 1.56 to 400 mg/kg/72 h were also performed. A maximum effect (Emax) model was used to determine the pharmacokinetic/pharmacodynamic (PK/PD) index that best described the dose-response data and to estimate the doses required to achieve a net bacteriostatic dose (SD) and a 1-log reduction in CFU/thigh. The pharmacokinetic studies demonstrated an area under the concentration-time curve (AUC) range of 26.8 to 276 mg·h/liter and half-lives of 4.2 to 8.2 h. MICs ranged from 0.125 to 0.5 μg/ml. The 2 highest single doses produced more than a 2-log kill and prolonged postantibiotic effects (PAEs) ranging from 36 to >72 h. The dose fractionation-response curves were similar, and the AUC/MIC ratio was the most predictive PD index (AUC/MIC, coefficient of determination [R2]=0.89; maximum concentration of drug in serum [Cmax]/MIC, R2=0.79; time [T]>MIC, R2=0.63). A ≥2-log kill was observed against all 9 S. aureus strains. The total drug 24-h AUC/MIC values associated with stasis and a 1-log kill for the 9 S. aureus strains were 371±130 and 510±227, respectively. NAI-107 demonstrated concentration-dependent killing and prolonged PAEs. The AUC/MIC ratio was the predictive PD index. Extensive killing was observed for S. aureus organisms, independent of the MRSA status. The AUC/MIC target should be useful for the design of clinical dosing regimens.

摘要

NAI-107是一种新型羊毛硫抗生素化合物,对革兰氏阳性菌具有强大的体外活性,包括耐甲氧西林金黄色葡萄球菌(MRSA)。本研究的目的是在中性粒细胞减少的小鼠大腿感染模型中检测NAI-107对包括MRSA在内的金黄色葡萄球菌菌株的活性。测定了血清药代动力学,并在单次皮下注射5、20和80mg/kg体重后进行了时间-杀菌研究。剂量分割包括总剂量范围为1.56至400mg/kg/72h,分为1、2、3或6剂。还进行了使用12小时给药间隔和1.56至400mg/kg/72h总剂量范围对9株金黄色葡萄球菌菌株(4株甲氧西林敏感金黄色葡萄球菌[MSSA]和5株MRSA)的治疗效果研究。使用最大效应(Emax)模型确定最能描述剂量反应数据的药代动力学/药效学(PK/PD)指数,并估计实现净抑菌剂量(SD)和使每大腿CFU减少1个对数所需的剂量。药代动力学研究表明,浓度-时间曲线下面积(AUC)范围为26.8至276mg·h/升,半衰期为4.2至8.2小时。MIC范围为0.125至0.5μg/ml。2个最高单剂量产生了超过2个对数的杀灭效果,并延长了抗生素后效应(PAE),范围从36至>72小时。剂量分割反应曲线相似,AUC/MIC比值是最具预测性的PD指数(AUC/MIC,决定系数[R2]=0.89;血清中药物最大浓度[Cmax]/MIC,R2=0.79;时间[T]>MIC,R2=0.63)。对所有9株金黄色葡萄球菌菌株均观察到≥2个对数的杀灭效果。与9株金黄色葡萄球菌菌株的停滞和1个对数杀灭相关的24小时总药物AUC/MIC值分别为371±130和510±227。NAI-107表现出浓度依赖性杀灭和延长的PAE。AUC/MIC比值是预测性的PD指数。观察到对金黄色葡萄球菌菌株有广泛的杀灭作用,与MRSA状态无关。AUC/MIC靶点应有助于临床给药方案的设计。

相似文献

3
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.糖肽类药物达巴万星的体内药效学活性。
Antimicrob Agents Chemother. 2007 May;51(5):1633-42. doi: 10.1128/AAC.01264-06. Epub 2007 Feb 16.

引用本文的文献

9
Bacteriocins: Potential for Human Health.细菌素:对人类健康的潜在影响。
Oxid Med Cell Longev. 2021 Apr 10;2021:5518825. doi: 10.1155/2021/5518825. eCollection 2021.

本文引用的文献

4
Vancomycin-resistant enterococci.耐万古霉素肠球菌。
Crit Care Clin. 2013 Oct;29(4):841-52. doi: 10.1016/j.ccc.2013.06.006.
5
New antibiotics for bad bugs: where are we?新型抗生素应对耐药菌:进展如何?
Ann Clin Microbiol Antimicrob. 2013 Aug 28;12:22. doi: 10.1186/1476-0711-12-22.
6
The future of antibiotics and resistance.抗生素与耐药性的未来。
N Engl J Med. 2013 Jan 24;368(4):299-302. doi: 10.1056/NEJMp1215093.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验